日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級(jí)生物類似抗體
  4. CCR9 (AZD7798 Biosimilar) Recombinant Monoclonal Antibody

CCR9 (AZD7798 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號(hào)：
    CSB-RA004848MB2HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    CCR9(AZD7798 Biosimilar Antibody)重組單克隆抗體是一種專為科研應(yīng)用開(kāi)發(fā)的生物試劑，可特異性靶向CCR9（C-C趨化因子受體9）蛋白。該產(chǎn)品基于重組DNA技術(shù)制備，通過(guò)將編碼特定抗體序列的基因?qū)胨拗骷?xì)胞進(jìn)行表達(dá)和純化，確保了批次間的高一致性和高純度。 CCR9作為G蛋白偶聯(lián)受體家族成員，在免疫調(diào)節(jié)、炎癥反應(yīng)及淋巴細(xì)胞歸巢中發(fā)揮關(guān)鍵作用。該抗體能夠高親和力結(jié)合CCR9的胞外結(jié)構(gòu)域，有效阻斷其與配體（如CCL25）的相互作用，為研究CCR9介導(dǎo)的信號(hào)通路、細(xì)胞遷移機(jī)制及相關(guān)疾病模型提供了可靠工具。 在科研場(chǎng)景中，該抗體可廣泛應(yīng)用于多種實(shí)驗(yàn)技術(shù)，包括及體外功能實(shí)驗(yàn)等。通過(guò)特異性識(shí)別CCR9，研究人員能夠精確檢測(cè)其在不同組織、細(xì)胞系中的表達(dá)水平，分析其亞細(xì)胞定位，并深入探究其在腫瘤發(fā)生、自身免疫性疾病及炎癥過(guò)程中的生物學(xué)功能。 產(chǎn)品嚴(yán)格遵循科研級(jí)試劑標(biāo)準(zhǔn)生產(chǎn)，經(jīng)過(guò)多步純化工藝去除雜質(zhì)，且通過(guò)SDS-PAGE、HPLC等質(zhì)控手段驗(yàn)證純度（通?！?5%）。此外，該抗體經(jīng)功能性檢測(cè)確保其結(jié)合活性，可滿足基礎(chǔ)研究、藥物靶點(diǎn)驗(yàn)證及機(jī)制探索等科研需求，為生命科學(xué)領(lǐng)域的相關(guān)研究提供有力支持。
  • Uniprot No.：
  • 基因名：
  • 別名：
    AZD7798 research-grade biosimilar; AZD 7798 research-grade biosimilar; AZD-7798 research-grade biosimilar ;CCR9 antibody; GPR28 antibody; C-C chemokine receptor type 9 antibody; C-C CKR-9 antibody; CC-CKR-9 antibody; CCR-9 antibody; G-protein coupled receptor 28 antibody; GPR-9-6 antibody; CD antigen CDw199 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human CCR9 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說(shuō)明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level.; (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.
  • 基因功能參考文獻(xiàn)：
    1. There were significantly increased CCR9 protein levels in failing human hearts. PMID: 27146447
    2. this study showed that CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. PMID: 26616645
    3. Results indicated that the expression levels of CCR9 in lesional skin may be a useful biologic marker of the clinical efficacy of infliximab therapy in psoriasis patients. PMID: 26507968
    4. Xray crystal structure of the CCR9 receptor in complex with vercirnon at 2.8 A resolution PMID: 27926729
    5. It plays a pathogenic role in liver diseases and it will be a therapeutic target of the diseases. PMID: 27795503
    6. that CCL25/CCR9 signal may provide cancer cells with chemotactic abilities through influencing several epithelial-mesenchymal transitionmarkers PMID: 27008282
    7. Studies indicate important roles played by chemokine ligand 25 (CCL25)/chemokine receptor 9 (CCR9) in tumorigenesis, tumor chemoresistance and metastasis. PMID: 26879872
    8. CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue. PMID: 26348893
    9. CCR9 mRNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group. PMID: 26279399
    10. CCR9-CCL25 interaction promoted proliferation and suppressed apoptosis of non-small cell lung cancer cells by activating the PI3K/Akt pathway. PMID: 25691296
    11. CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma. PMID: 26168791
    12. We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance PMID: 26006007
    13. High CCR9 expression is associated with the pathogenesis of ulcerative colitis. PMID: 24936795
    14. Expression of CCR9 and CCL25, the only natural ligand of CCR9, was significantly higher (p<0.0001) in NSCLC tissues and serum respectively, compared to their respective controls. PMID: 25296976
    15. activation of Notch1 has a dominant-negative effect on Ccr9 transcription and that Notch1 and E proteins control the dynamic expression of Ccr9 during T cell development. PMID: 25710912
    16. The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors. PMID: 24870448
    17. results suggest that CCR9 can act as a novel prognostic marker and therapeutic target for hepatocellular carcinoma PMID: 24481516
    18. CCR9 expression is elevated in the nodal lymphomas of patients with GI involvement PMID: 24828696
    19. Only rotavirus specific CD4 T cells expressed intestinal homing receptors alpha4beta7 and CCR9. PMID: 24606696
    20. Data suggest that P-glycoprotein associate with the F-actin cytoskeleton through ezrin/radixin/moesin (ERM) in CCR9/CCL25 induced multidrug resistance of acute T-lymphocytic leukemia (T-ALL) cells. PMID: 23326330
    21. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. PMID: 21984373
    22. We provide the first evidence that CCR9 and its natural ligand CCL25 are highly expressed by ovarian cancer tissue and their expression correlates with histological subtypes. PMID: 21637913
    23. CCL25 enhanced the expression of MMP-1, -9, -11 and -13 active proteins by BrCa cells in a CCR9-dependent fashion. PMID: 21344163
    24. CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system PMID: 21511186
    25. The high fraction of circulating IgA+ and IgG+ B cells expressing CCR9 and CCR10 in the first months of life indicates activation of naive B cells in the gut, coinciding with bacterial colonization. PMID: 21075690
    26. TLR2 ligands induce CCR9 and CCR10 expression by circulating B-cells and increase their chemotaxis. TLR2 stimulation also induced J chain and IgA production demonstrating the induction of mucosal-like antibody secreting cells. PMID: 20947433
    27. CCR9 expression by monocytes is increased in rheumatoid arthritis PMID: 20738854
    28. Results demonstrate enhanced pancreatic intraepithelial neoplasia and pancreatic cancer cell proliferation with activation of CCR9 by its selective ligand CCL25 PMID: 19756884
    29. Studies indicate that D6 chemokine receptor(CCR-9) may act as scavenging decoys and are involved in clearance of chemokines. PMID: 20036838
    30. more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin graft vs. host disease. PMID: 19525985
    31. over-expressed TECK interacts with CCR9 on the endometrial stromal cells in the endometriotic milieu, which may contribute to the onset and progression of endometriosis. PMID: 20081876
    32. A subset of CCR9+ T cells from normal donors has characteristics of mucosal T cells in terms of activated phenotype, proliferative response to anti-CD2 stimulation, a Th1 or Tr1 cytokine profile, and support for Ig production by cocultured B cells. PMID: 12816994
    33. CCR9 selectively induced T-ALL CD4+ T-cell chemotaxis and adhesion. PMID: 14559839
    34. High Expression of CCR9 is associated with prostate cancer cell migration and invasion PMID: 15623660
    35. involved in the pathogenesis of lymphatic filarial disease PMID: 15717282
    36. CCR9 overexpression is associated with Adult T-cell leukemia cells infiltrating gastrointestinal tract PMID: 17205512
    37. CCR9 expression is reduced on epithelial and lamina propria T cells in untreated celiac disease. Down-regulation of CCR9 persists in intraepithelial T cells from well-treated patients. Possible ongoing immune activation preferentially within epithelium. PMID: 17570212
    38. CCR9 is expressed on human melanoma cells and participates in the enhanced motility of melanoma cells and is likely a "homing receptor" for melanoma to the small bowel. PMID: 18245518
    39. Functionally active CCR9 on melanoma cells facilitates metastasis to the small intestine which may explain high incidence of metastis to the small intestine. PMID: 18245522

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Multi-pass membrane protein.
  • 蛋白家族：
    G-protein coupled receptor 1 family
  • 組織特異性：
    Highly expressed in the thymus and low in lymph nodes and spleen.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 1610

    OMIM: 604738

    KEGG: hsa:10803

    STRING: 9606.ENSP00000350256

    UniGene: Hs.225946



×
生命科學(xué)計(jì)算平臺(tái)